Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and Neuroblastoma

irinotecan has been researched along with Neuroblastoma in 95 studies

Research

Studies (95)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (9.47)18.2507
2000's37 (38.95)29.6817
2010's35 (36.84)24.3611
2020's14 (14.74)2.80

Authors

AuthorsStudies
Aherne, GW; Box, G; Boxall, KJ; Collins, I; de Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Lainchbury, M; Matthews, TP; McHardy, T; Raynaud, FI; Reader, JC; Valenti, MR; Walton, MI1
Angeles, C; Enzor, LA; Levesque, AA; Pappalardo, RM; Puli, P1
Hamada, M; Ichikawa, D; Imaya, M; Kawashima, N; Kojima, S; Miwata, S; Muramatsu, H; Narita, A; Narita, K; Nishikawa, E; Nishio, N; Takahashi, Y; Wakamatsu, M; Yamamori, A; Yoshida, T1
Castañeda, A; Chamizo, A; Flores, MA; Garraus, M; Gorostegui, M; Lazaro, JJ; Miralles, SL; Mora, J; Muñoz, JP; Patiño, SC; Santa-Maria, V; Varo, A1
Burrow, TA; Eslinger, C; Koneru, B; Macha, SJ; McCoy, K; Nance, J; Rahman, RL; Reynolds, CP; Ronaghan, CA; Savitski, D; Zhu, C1
Bagatell, R; Carlowicz, C; Cash, T; Choe, M; Desai, AV; Federico, SM; Foster, JH; Granger, M; Lerman, BJ; Li, Y; Macy, ME; Mody, R; Morgenstern, DA; Pinto, N; Rafael, MS; Ranavaya, A; Sadanand, A; Shusterman, S; Somers, K; Streby, KA; Weiss, BD; Yazdani, S; Zeno, RN1
Asgharzadeh, S; Bagatell, R; Birstler, J; Diccianni, MB; Erbe, AK; Feils, AS; Hung, JT; Kim, K; London, WB; Maris, JM; Mathew, V; Mody, R; Naranjo, A; Parisi, MT; Park, J; Servaes, S; Shulkin, BL; Sondel, PM; Yu, AL; Zhang, FF1
Hiramatsu, H; Iwai, A; Kato, I; Kobushi, H; Kozuki, K; Kubota, H; Obu, S; Saida, S; Takita, J; Tanaka, K; Tasaka, K; Uchihara, Y; Umeda, K1
Cole, KA; Fox, E; Ijaz, H; Liu, X; Maris, JM; Minard, CG; Reid, JM; Santi, M; Surrey, LF; Voss, S; Weigel, BJ1
Erickson, SW; Gorlick, R; Guo, Y; Houghton, PJ; Kolb, EA; Kurmasheva, RT; Maris, JM; Mosse, YP; Smith, MA; Teicher, BA1
Asgharzadeh, S; Bagatell, R; Birstler, J; Diccianni, MB; Felder, M; Glade-Bender, J; Hank, JA; Katzenstein, H; London, WB; Maris, JM; Mody, R; Naranjo, A; Parisi, MT; Park, JR; Servaes, SE; Shulkin, BL; Sondel, PM; Yu, AL; Zhang, FF1
Chen, WH; Hindle, A; Koneru, B; Lopez-Barcons, L; Makena, MR; Nguyen, TH; Reynolds, CP1
Dwivedi, T; Gupta, AK; Gupta, R; Meena, JP; Ramachandran, M; Seth, R; Singh, U1
Corbacioglu, S; Heise, T; Leister, J; Matthes, M; Penkivech, G; Sommer, G; Waetzig, R1
Berkovich, R; Cohn, SL; Czarnecki, S; DuBois, SG; Goldsmith, KC; Goodarzian, F; Granger, MM; Groshen, S; Haas-Kogan, DA; Irwin, MS; Ji, L; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Park, JR; Pinto, N; Shamirian, A; Shimada, H; Shusterman, S; Tsao-Wei, D; Twist, CJ; Villablanca, JG; Vo, KT; Weiss, B; Yanik, GA1
Carcaboso, AM; Castillo-Ecija, H; Cheung, NKV; Cuadrado-Vilanova, M; de Torres, C; Ferrandiz, MM; Glisoni, R; Jungbluth, A; Kuplennik, N; Lavarino, C; Monterrubio, C; Mora, J; Olaciregui, NG; Paco, S; Pascual-Pasto, G; Sosnik, A; Vila-Ubach, M1
Allan, S; Byrne, JA; Cheung, L; Eden, GL; Flemming, CL; Fletcher, JI; Gamble, LD; Gifford, AJ; Haber, M; Hanssen, KM; Henderson, MJ; Murray, J; Norris, MD; Ruhle, M; Saletta, F; Schuetz, JD; Tan, A; Tivnan, A; Truong, AM; Valli, E; Yu, DMT1
Alferiev, I; Brodeur, GM; Chorny, M; Guan, P; Guerrero, DT; Kolla, V; Moorthy, GS; Nguyen, F1
Grygier, B; Jantas, D; Lasoń, W; Zatorska, J1
Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I1
Berbegall, AP; Bondarenko, GI; Dubrovskyi, O; Giles, FJ; Hendrix, MJ; Mazar, AP; Navarro, S; Noguera, R; O'Halloran, TV; Ugolkov, AV1
Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B1
Hashimoto, K; Inoue, M; Inoue, Y; Koike, Y; Kusunoki, M; Matsushita, K; Mohri, Y; Okugawa, Y; Otake, K; Saigusa, S; Tanaka, K; Uchida, K; Ueeda, M1
Armstrong, AE; Cohn, RA; Dargart, J; Gosiengfiao, Y; Matossian, D; Reichek, J; Walterhouse, DO1
Brodeur, GM; Croucher, JL; Gordon, WP; Iyer, R; Li, N; Liu, B; Loren, J; Molteni, V; Tuntland, T1
Allen, S; Bent, M; Courtier, J; DuBois, SG; Hawkins, R; Hilton, JF; Hollinger, F; Matthay, KK; Mosse, YP1
Alferiev, IS; Brodeur, GM; Chorny, M; Croucher, JL; Iyer, R; Kolla, V; Levy, RJ; Mangino, JL1
Adamo, RF; Alferiev, IS; Brodeur, GM; Chorny, M; Croucher, JL; Fishbein, I; Iyer, R; Kolla, V; Levy, RJ; Mangino, JL; Zhang, K1
Carcaboso, AM; Glisoni, R; Lavarino, C; Monterrubio, C; Mora, J; Paco, S; Rodríguez, E; Schaiquevich, P; Sosnik, A; Vila-Ubach, M1
Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M1
Brodeur, GM; Cam, N; Croucher, JL; Golden, RL; Guan, P; Hornby, Z; Iyer, R; Kolla, V; Li, G; MacFarland, SP; Naraparaju, K; Wehrmann, L; Wei, G1
Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L1
Armstrong, MB; Castle, VP; Mody, R; Opipari, AW; Schumacher, KR; Yanik, GA1
Nariai, H; Natsumeda, T; Oto, Y; Sato, Y; Shitara, T; Taniuchi, M1
Assadourian, S; Brooks, M; Cisar, L; Couanet, D; Gentet, JC; Geoerger, B; Geoffray, A; Giammarile, F; Michon, J; Morland, B; Pichon, F; Rubie, H; Schell, M; Stockdale, E; Vassal, G1
Hosoi, H; Iehara, T; Misawa, A; Osone, S; Sugimoto, T; Tsuchiya, K1
Crews, KR; Daldrup-Link, HE; Groshen, S; Hawkins, RA; Jackson, HA; Maris, JM; Matthay, KK; Park, JR; Reynolds, CP; Stewart, CF; Villablanca, JG; Wagner, LM1
Kaneko, M; Kaneko, S; Suzuki, K1
Cusano, G; D'Incalci, M; Di Francesco, AM; Forestieri, D; Meco, D; Patriarca, V; Pisano, C; Riccardi, R; Servidei, T; Zucchetti, M1
Balamuth, N; Brodeur, GM; Evans, AE; Ho, R; Iyer, R; Maris, JM; Minturn, JE; Qi, X; Zhao, H1
Becherini, P; Cilli, M; Emionite, L; Greenberger, LM; Horak, ID; Loi, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P1
Cai, W; Cui, W; Harutyunyan, N; Ji, L; Keshelava, N; Maldonado, NV; Reynolds, CP; Sposto, R1
Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Yataghene, K1
Cheung, NK; Kramer, K; Kushner, BH; Modak, S4
Bagatell, R; Cohn, SL; Kretschmar, C; London, WB; Maris, JM; Stewart, CF; Voss, SD; Wagner, LM1
Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M1
Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K1
Billups, CA; Davidoff, AM; Furman, WL; Hawkins, D; Houghton, PJ; Kovach, S; McCarville, MB; McGregor, LM; McPherson, V; Onciu, M; Santana, VM; Stewart, CF; Wu, J1
Fukushima, T; Kaneko, M; Kaneko, S1
Chesler, L; DuBois, SG; Goodarzian, F; Groshen, S; Hawkins, R; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Shimada, H; Stewart, C; Tagen, M; Tsao-Wei, D; Villablanca, JG; Yanik, G1
Brodeur, GM; Brown, JL; Evans, AE; Ho, R; Iyer, R; Light, JE; Minturn, JE; Simpson, AM; Thress, K; Varela, CR; Zhao, H1
Degenhardt, YY; Diskin, SJ; Haglund, E; Maris, JM; Mayes, PA; Moy, C; Toporovskya, Y; Wood, A; Wooster, R1
Bucci, F; Cusano, G; Di Francesco, AM; Meco, D; Patriarca, V; Pierri, F; Pisano, C; Riccardi, R; Torella, AR1
Marutsuka, K; Moritake, H; Nunoi, H; Shimonodan, H; Takeshima, H; Yamada, A; Yokogami, K1
Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS1
Ashmun, RA; Burger, RA; Danks, MK; Guichard, SM; Harris, LC; Houghton, PJ; Morton, CL; Potter, PM; Straign, CM; Wagner, LM1
Cheshire, P; Dodds, HM; Hanna, S; Houghton, P; Rivory, LP; Stewart, CF; Tobin, PJ1
Kuroiwa, M; Shimada, A; Shitara, T; Suzuki, N; Toki, F; Tsuchida, Y1
Ikeda, H; Kuroiwa, M; Shitara, T; Tsuchida, Y1
Aubert, G; Bénard, J; Calvet, L; Larsen, A; Lavelle, F; Morizet, J; Pondarré, C; Santos, A; Terrier-Lacombe, MJ; Vassal, G1
Aubert, G; Bénard, J; Calvet, L; Merlin, JL; Morizet, J; Opolon, P; Santos, A; Schellens, JH; Terrier-Lacombe, MJ; Valent, A; Vassal, G1
Gräslund, A; Jarvet, J; Kogner, P; Lindskog, M; Spenger, C1
Allen, JD; Cohn, SL; Flemming, C; Haber, M; London, WB; Marshall, GM; Norris, MD; Scheffer, GL; Smith, J; Tanabe, K; Tobin, P; Wielinga, P1
Barone, G; Carminati, P; D'Incalci, M; Di Francesco, AM; Frapolli, R; Meco, D; Pisano, C; Riccardi, A; Riccardi, AS; Riccardi, R; Rutella, S; Zucchetti, M1
Inagaki, J; Inoue, M; Kawa, K; Sakata, N; Yagi, K; Yasui, M1
Calvet, L; Elie, N; Geoerger, B; Joseph, JM; Machet, L; Morizet, J; Opolon, P; Regairaz, M; Vassal, G1
Hanada, R; Kawa, K; Manabe, A; Matsunaga, T; Mimaya, J; Mugishima, H; Shimada, A; Shitara, T; Sugimoto, T; Tsuchida, Y; Tsurusawa, M1
Chen, CS; Chen, TC; Hofman, FM; Kardosh, A; Liu, YT; Petasis, NA; Pyrko, P; Schönthal, AH; Soriano, N; Uddin, J1
Danks, MK; Hatfield, MJ; Lee, RE; Potter, PM; Qi, J; Remack, JS; Virga, KG; Yoon, KJ1
Aboody, KS; Bush, RA; Danks, MK; Garcia, E; Gillespie, S; Glackin, CA; Justus, KA; Kim, SU; Metz, MZ; Najbauer, J; Phelps, DA; Potter, PM; Remack, JS; Yoon, KJ1
Aboody, KS; Bush, RA; Danks, MK; Garcia, E; Kim, SU; Metz, MZ; Najbauer, J; Potter, PM; Remack, JS; Tsurkan, L; Wierdl, M; Yoon, KJ1
Aoyama, C; Hosoya, R; Kamiya, T; Kato, I; Manabe, A; Ogawa, C; Ozawa, M; Takahashi, H; Takusagawa, A; Yokoyama, K1
Billups, CA; Danks, MK; McLendon, RE; Wagner, LM; Weiss, BD; Yoon, KJ1
Fujii, S; Hayashi, R; Kawashima, M; Kiyota, N; Minami, H; Ogino, T; Ohtsu, A; Tahara, M1
Ishibashi, M; Kaneko, M; Kaneko, S1
Aoyama, T; Kaneda, N; Kaneko, M; Komuro, H; Li, P; Nakajima, K; Tsuchida, Y; Yokomori, K1
Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM1
Cheshire, PJ; Houghton, JA; Houghton, PJ; Luo, X; Richmond, L; Stewart, CF; Thompson, J; Zamboni, WC1
Crom, WR; Houghton, PJ; Stewart, CF; Zamboni, WC1
Choi, SH; Tsuchida, Y; Yang, HW1
Ardouin, P; Bénard, J; Boland, I; Cappelli, C; Gouyette, A; Hartmann, O; Morizet, J; Pondarré, C; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM1
Cheshire, PJ; Hanna, SK; Houghton, PJ; Lou, X; Richmond, LB; Stewart, CF; Thompson, J; Zamboni, WC1
Cheshire, PJ; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L; Stewart, CF; Thompson, J; Zamboni, WC1
Bowman, LC; Furman, WL; Hoffer, FA; Houghton, PJ; Ma, MK; Meyer, WH; Pappo, AS; Poquette, CA; Pratt, CB; Santana, VM; Stewart, CF; Walter, AW; Zamboni, WC1
Groshen, S; Keshelava, N; Reynolds, CP1
Danks, MK; Guichard, SM; Harris, LC; Iyengar, RV; Khanna, R; Krull, EJ; Mason, SE; Pawlik, CA; Potter, PM1
Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M1
Burger, RA; Danks, MK; Harris, LC; Iyengar, RV; Krull, EJ; Pawlik, CA; Phelps, DA; Potter, PM1
Burger, RA; Danks, MK; Guichard, SM; Harris, LC; Krull, EJ; Meck, MM; Potter, PM; Wagner, LM; Wierdl, M1
Agata, H; Fujimoto, T; Hirota, T; Hori, T; Kawai, N; Kitagawa, S; Konno, K; Sawada, K; Tsurusawa, M1
Houghton, PJ; Santana, VM1
Asami, K; Kaneko, M; Kishimoto, T; Matsunaga, T; Mimaya, J; Mugishima, H; Sawada, T; Suita, S; Tsuchida, Y; Yagi, K1

Reviews

1 review(s) available for irinotecan and Neuroblastoma

ArticleYear
How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
    ESMO open, 2022, Volume: 7, Issue:2

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Glycolipids; Granulocyte-Macrophage Colony-Stimulating Factor; Hospitals; Humans; Irinotecan; Neuroblastoma; Spain; Temozolomide; United States

2022

Trials

15 trial(s) available for irinotecan and Neuroblastoma

ArticleYear
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
    Cancer, 2023, 07-15, Volume: 129, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cerebellar Neoplasms; Child; Humans; Irinotecan; Medulloblastoma; Neuroblastoma; Protein-Tyrosine Kinases; Rhabdomyosarcoma

2023
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 07-01, Volume: 38, Issue:19

    Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Infant; Irinotecan; Male; Neuroblastoma; Survival Analysis; Temozolomide

2020
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 11-01, Volume: 39, Issue:31

    Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neuroblastoma; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vincristine; Vorinostat; Young Adult

2021
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
    British journal of cancer, 2015, Feb-17, Volume: 112, Issue:4

    Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Radiotherapy Dosage; Vincristine; Young Adult

2015
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Apr-20, Volume: 34, Issue:12

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult

2016
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:16

    Topics: Abdominal Neoplasms; Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infant; Injections, Intravenous; Irinotecan; Male; Neoplasm Recurrence, Local; Neuroblastoma; Prospective Studies; Thoracic Neoplasms; Treatment Outcome; Young Adult

2008
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-10, Volume: 27, Issue:8

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Recurrence; Temozolomide

2009
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-10, Volume: 29, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Humans; Infant; Irinotecan; Male; Neuroblastoma; Temozolomide

2011
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Female; Gefitinib; Homovanillic Acid; Humans; Immunohistochemistry; Infant; Infant, Newborn; Irinotecan; L-Lactate Dehydrogenase; Male; Neoplasm Proteins; Neuroblastoma; Pilot Projects; Quinazolines; Risk Factors; Treatment Outcome; Tumor Burden; Vanilmandelic Acid

2012
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, May-01, Volume: 18, Issue:9

    Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Iodine Radioisotopes; Irinotecan; Male; Maximum Tolerated Dose; Neuroblastoma; Prognosis; Tissue Distribution; Vincristine; Young Adult

2012
Current treatment and future directions in neuroblastoma.
    Indian journal of pediatrics, 2003, Volume: 70, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Endostatins; Humans; Infant; Irinotecan; Neoplasm Staging; Neuroblastoma; Prospective Studies; Survival Rate

2003
Irinotecan for children with relapsed solid tumors.
    Pediatric hematology and oncology, 2006, Volume: 23, Issue:2

    Topics: Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Neuroblastoma; Recurrence; Remission Induction; Rhabdomyosarcoma; Tumor Burden; Wilms Tumor

2006
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Neoplasms; Neuroblastoma; Subrenal Capsule Assay; Treatment Outcome

1999
[Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:13

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Irinotecan; Neuroblastoma

2001
Phase I study of irinotecan in pediatric patients with malignant solid tumors.
    Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Camptothecin; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Japan; Leiomyosarcoma; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Neoplasm Proteins; Neuroblastoma; Neuroectodermal Tumors, Primitive; Topoisomerase I Inhibitors; Treatment Outcome

2002

Other Studies

79 other study(ies) available for irinotecan and Neuroblastoma

ArticleYear
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
    Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22

    Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Checkpoint Kinase 1; Child; Colonic Neoplasms; DNA Damage; Drug Design; Humans; Mice; Mice, Nude; Mice, Transgenic; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2012
p53 oligomerization status as an indicator of sensitivity of p53-wildtype neuroblastomas to the combination of DNA damaging agent and Chk1 inhibitor.
    PloS one, 2022, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Damage; DNA, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; Staurosporine; Topoisomerase I Inhibitors

2022
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.
    Cancer medicine, 2022, Volume: 11, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Retrospective Studies

2022
Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
    Cancer research, 2022, Sep-16, Volume: 82, Issue:18

    Topics: Animals; Carcinoma; Humans; Irinotecan; Mice; Neuroblastoma; Sarcoma; Telomerase; Telomere; Telomere Homeostasis; Tumor Suppressor Protein p53

2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-20, Volume: 41, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Irinotecan; Neuroblastoma; Progression-Free Survival; Retrospective Studies; Temozolomide

2023
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
    Journal for immunotherapy of cancer, 2023, Volume: 11, Issue:2

    Topics: Child; Genotype; Granulocyte-Macrophage Colony-Stimulating Factor; Histocompatibility Antigens; Humans; Immunotherapy; Irinotecan; Leukocytes, Mononuclear; Ligands; Neuroblastoma; Receptors, KIR; Recurrence

2023
High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Retrospective Studies; Salvage Therapy; Temozolomide

2023
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; Female; Humans; Irinotecan; Kidney Neoplasms; Mice; Mice, SCID; Neoplasms, Experimental; Neuroblastoma; Pyrazoles; Pyrimidinones; Wilms Tumor; Xenograft Model Antitumor Assays

2020
The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma.
    Anti-cancer drugs, 2021, 03-01, Volume: 32, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Guanine; Humans; Irinotecan; Mice; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Real-Time Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Up-Regulation

2021
Robust and sustained antibody response to SARS-CoV-2 in a child pre and post autologous hematopoietic stem cell transplant.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:5

    Topics: Antibodies, Viral; Antineoplastic Agents; Child, Preschool; COVID-19; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunoglobulin G; Immunoglobulin M; Irinotecan; Male; Neuroblastoma; SARS-CoV-2; Temozolomide; Transplantation, Autologous

2021
Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
    International journal of medical sciences, 2021, Volume: 18, Issue:1

    Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Irinotecan; Naphthyridines; Neuroblastoma; Purines; Pyrimidines; Signal Transduction; Sirolimus; Temozolomide; Thiourea; TOR Serine-Threonine Kinases

2021
Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, 06-10, Volume: 255

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Child, Preschool; Drug Liberation; Extracellular Fluid; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Irinotecan; Male; Mice, Nude; N-Acetylgalactosaminyltransferases; Nanoparticles; Neuroblastoma; Tissue Distribution; Xenograft Model Antitumor Assays

2017
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 83

    Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Doxycycline; Heterografts; Irinotecan; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Neuroblastoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017
Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 06-01, Volume: 24, Issue:11

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Humans; Injections, Intralesional; Irinotecan; Mice; Nanoparticles; Neuroblastoma; Prodrugs; Recurrence; Retreatment; Survival Rate; Tissue Distribution; Tocopherols; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays

2018
Allosteric and Orthosteric Activators of mGluR8 Differentially Affect the Chemotherapeutic-Induced Human Neuroblastoma SH-SY5Y Cell Damage: The Impact of Cell Differentiation State.
    Basic & clinical pharmacology & toxicology, 2018, Volume: 123, Issue:4

    Topics: Acetanilides; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Excitatory Amino Acid Agonists; Humans; Irinotecan; Neuroblastoma; Neurogenesis; Phenotype; Receptors, Metabotropic Glutamate; Signal Transduction; Thioglycolates

2018
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
    Journal of immunology research, 2018, Volume: 2018

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53

2018
9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.
    Anti-cancer drugs, 2018, Volume: 29, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Female; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Irinotecan; Maleimides; Mice; Mice, Nude; Neuroblastoma; Xenograft Model Antitumor Assays

2018
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Neuroblastoma; Osteosarcoma; Remission Induction; Retreatment; Rhabdomyosarcoma; Sarcoma, Ewing; Survival Rate; Temozolomide; Vincristine; Wilms Tumor

2019
Clinical implications of CES2 RNA expression in neuroblastoma.
    Journal of pediatric surgery, 2013, Volume: 48, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Neuroblastoma; RNA; Tumor Cells, Cultured

2013
Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Dacarbazine; Female; Humans; Irinotecan; Neuroblastoma; Renal Dialysis; Renal Insufficiency; Temozolomide; Treatment Outcome

2014
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Drugs, Investigational; Half-Life; Humans; Irinotecan; Membrane Glycoproteins; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Receptor, trkB; Survival Analysis; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2015
Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
    Cancer letters, 2015, May-01, Volume: 360, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Humans; Irinotecan; Mice; Mice, Nude; Nanoparticles; Neuroblastoma; Prodrugs; Tissue Distribution; Xenograft Model Antitumor Assays

2015
Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.
    Biomaterials, 2015, Volume: 51

    Topics: alpha-Tocopherol; Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Humans; Irinotecan; Mice, Nude; Nanoparticles; Neuroblastoma; Particle Size; Prodrugs; Treatment Outcome

2015
Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts.
    Pharmaceutical research, 2015, Volume: 32, Issue:9

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; beta-Cyclodextrins; Camptothecin; Heterografts; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Mice; Mice, Nude; Microdialysis; Neuroblastoma

2015
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
    Nature communications, 2015, Nov-25, Volume: 6

    Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway

2015
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
    Cancer letters, 2016, Mar-28, Volume: 372, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Humans; Indazoles; Irinotecan; Membrane Glycoproteins; Mice, Nude; Neuroblastoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays

2016
Bortezomib as a therapeutic candidate for neuroblastoma.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; NF-kappa B; Pyrazines

2008
How can we ameliorate irinotecan-associated diarrhea in children with poor compliance for oral cephalosporin?
    Pediatric blood & cancer, 2009, Volume: 52, Issue:1

    Topics: Camptothecin; Cephalosporins; Child; Diarrhea; Humans; Irinotecan; Male; Neuroblastoma; Patient Compliance

2009
Low-dose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma.
    Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:11

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Female; Humans; Infant; Irinotecan; Magnetic Resonance Imaging; Neuroblastoma; Palliative Care; Radiography; Treatment Outcome

2008
Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
    Cancer science, 2009, Volume: 100, Issue:11

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Celecoxib; Cell Proliferation; Child, Preschool; Cyclooxygenase 2 Inhibitors; Female; Humans; Infant; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neuroblastoma; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays

2009
Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Chromatography, High Pressure Liquid; Half-Life; Humans; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Rhabdomyosarcoma; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays

2010
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carbazoles; Cyclophosphamide; Dacarbazine; Enzyme Activation; Furans; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Topotecan; Xenograft Model Antitumor Assays

2010
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-01, Volume: 16, Issue:19

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Neuroblastoma; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors

2010
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.
    British journal of cancer, 2010, Oct-26, Volume: 103, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Dacarbazine; Female; Guanine; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Xenograft Model Antitumor Assays

2010
High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infant; Irinotecan; Male; Neuroblastoma; Retrospective Studies; Vincristine

2011
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
    Pediatric blood & cancer, 2011, Volume: 56, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome

2011
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
    Brain tumor pathology, 2011, Volume: 28, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine

2011
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
    Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome

2011
Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
    International journal of clinical oncology, 2013, Volume: 18, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Synergism; Humans; Irinotecan; Male; Mice; Neuroblastoma; Pyrazoles; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays

2013
AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Xenograft Model Antitumor Assays

2012
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
    International journal of cancer, 2013, Feb-01, Volume: 132, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Colonic Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Sarcosine; Temozolomide

2013
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Cerebellar Neoplasms; Child; Comet Assay; DNA Damage; Drug Synergism; Humans; Irinotecan; Medulloblastoma; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Platinum Compounds; Xenograft Model Antitumor Assays

2012
Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child, Preschool; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Prognosis; Promoter Regions, Genetic; Stem Cell Transplantation; Temozolomide; Transplantation, Autologous; Tumor Suppressor Proteins

2013
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.
    Bone marrow transplantation, 2013, Volume: 48, Issue:5

    Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide

2013
Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.
    Cancer research, 2002, Sep-01, Volume: 62, Issue:17

    Topics: Adenoviridae; Animals; Bone Marrow; Bone Marrow Purging; Camptothecin; Carboxylic Ester Hydrolases; DNA, Complementary; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Pilot Projects; Prodrugs

2002
The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:2

    Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylic Ester Hydrolases; Chromatography, High Pressure Liquid; Female; Glucuronidase; Humans; Irinotecan; Kinetics; Mice; Mice, SCID; Microdialysis; Neoplasm Transplantation; Neuroblastoma; Transplantation, Heterologous

2002
Successful clinical response to irinotecan in relapsed neuroblastoma.
    Medical and pediatric oncology, 2003, Volume: 40, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Infant; Irinotecan; Lung Neoplasms; Mediastinal Neoplasms; Neoplasm Recurrence, Local; Neuroblastoma; Radiography; Salvage Therapy; Topoisomerase I Inhibitors; Treatment Outcome

2003
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 1

    Topics: Adolescent; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Infant; Irinotecan; Male; Mesna; Neuroblastoma; Retrospective Studies; Topotecan

2004
In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
    Cancer research, 2004, May-01, Volume: 64, Issue:9

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Differentiation; Cell Division; Child; Child, Preschool; Diterpenes; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Retinaldehyde; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays

2004
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Abdominal Neoplasms; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Topoisomerase I Inhibitors; Transplantation, Heterologous

2004
Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
    Journal of the National Cancer Institute, 2004, Oct-06, Volume: 96, Issue:19

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Choline; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Hydrocarbons; Irinotecan; Magnetic Resonance Spectroscopy; Matched-Pair Analysis; Methane; Neuroblastoma; Predictive Value of Tests; Protons; Rats; Rats, Nude; Reproducibility of Results; Transplantation, Heterologous

2004
Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.
    Cancer, 2005, Feb-15, Volume: 103, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Nervous System Neoplasms; Neuroblastoma; Palliative Care; Quality of Life; Retrospective Studies; Treatment Outcome

2005
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; DNA, Complementary; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; In Vitro Techniques; Irinotecan; Multidrug Resistance-Associated Proteins; Neuroblastoma; Polymerase Chain Reaction; Prognosis; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; Tumor Cells, Cultured

2005
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
    Biochemical pharmacology, 2005, Oct-15, Volume: 70, Issue:8

    Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Comet Assay; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Irinotecan; Neuroblastoma; Topotecan

2005
Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:11

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Retroperitoneal Neoplasms; Topoisomerase I Inhibitors

2005
Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.
    Oncogene, 2006, May-25, Volume: 25, Issue:22

    Topics: Animals; Camptothecin; Carrier Proteins; Child, Preschool; Cytokines; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation; Humans; Irinotecan; Male; Mice; Neovascularization, Pathologic; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2006
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
    Molecular cancer, 2006, May-18, Volume: 5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Celecoxib; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Neuroblastoma; Promoter Regions, Genetic; Pyrazoles; Sulfonamides; Survivin; Transcription, Genetic; Transfection; Xenograft Model Antitumor Assays

2006
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:6

    Topics: Animals; Camptothecin; Carboxylesterase; Catalysis; Cell Division; Etoposide; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Neuroblastoma; Prodrugs; Rabbits; Tumor Cells, Cultured

2006
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neuroblastoma; Quality of Life; Temozolomide; Treatment Outcome

2006
Development of a tumor-selective approach to treat metastatic cancer.
    PloS one, 2006, Dec-20, Volume: 1

    Topics: Animals; Base Sequence; Camptothecin; Carboxylic Ester Hydrolases; Cell Line; Cell Line, Tumor; DNA Primers; Embryonic Stem Cells; Humans; Irinotecan; Mice; Mice, SCID; Multipotent Stem Cells; Neoplasm Metastasis; Neoplasm Transplantation; Neuroblastoma; Prodrugs; Rabbits; Recombinant Proteins; Transduction, Genetic; Transplantation, Heterologous

2006
Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.
    Cancer research, 2007, Jan-01, Volume: 67, Issue:1

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Combined Modality Therapy; Disease-Free Survival; DNA, Complementary; Genetic Therapy; Humans; Irinotecan; Mice; Neuroblastoma; Prodrugs; Telencephalon; Transduction, Genetic; Xenograft Model Antitumor Assays

2007
Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:3

    Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Iodine Radioisotopes; Irinotecan; Neuroblastoma; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine

2008
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Irinotecan; Mice; Mice, SCID; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neuroblastoma; Nuclear Proteins; Temozolomide; Tumor Suppressor Proteins

2007
Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.
    Cancer, 2008, Feb-15, Volume: 112, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Docetaxel; Esthesioneuroblastoma, Olfactory; Female; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Taxoids

2008
Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
    Cancer science, 2008, Volume: 99, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Immunoenzyme Techniques; Infant; Irinotecan; Male; Mice; Neovascularization, Pathologic; Neuroblastoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2008
Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
    Medical and pediatric oncology, 1994, Volume: 23, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromosomes, Human, Pair 20; DNA Topoisomerases, Type I; Female; Genes, myc; Humans; Injections, Intraperitoneal; Irinotecan; Lethal Dose 50; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neuroblastoma; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured

1994
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
    British journal of cancer, 1996, Volume: 74, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Paclitaxel; Thiotepa; Topoisomerase I Inhibitors; Transplantation, Heterologous

1996
Efficacy of oral irinotecan against neuroblastoma xenografts.
    Anti-cancer drugs, 1997, Volume: 8, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child, Preschool; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infant; Irinotecan; Mice; Mice, Inbred CBA; Neuroblastoma; Topoisomerase I Inhibitors; Transplantation, Heterologous

1997
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:3

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Proteins; Camptothecin; Female; Injections, Intravenous; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; Protein Binding

1997
Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice.
    Cancer letters, 1998, Feb-13, Volume: 124, Issue:1

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Injections, Intraperitoneal; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neuroblastoma

1998
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:12

    Topics: Adrenal Glands; Animals; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Ganglioneuroblastoma; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Remission Induction; Topotecan; Transplantation, Heterologous

1997
Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Injections, Intravenous; Irinotecan; Male; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; Prodrugs; Transplantation, Heterologous; Tumor Cells, Cultured

1998
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Injections, Intravenous; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Recurrence, Local; Neuroblastoma; Thymectomy; Transplantation, Heterologous; Tumor Cells, Cultured

1997
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:1

    Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured

2000
Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2000, Volume: 1, Issue:5 Pt 1

    Topics: Animals; Blotting, Northern; Blotting, Southern; Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Dose-Response Relationship, Drug; Genetic Vectors; Humans; Irinotecan; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Tumor Cells, Cultured

2000
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:10

    Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors

2000
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
    Cancer research, 2001, Apr-01, Volume: 61, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Glioblastoma; Humans; Immunoblotting; Irinotecan; MyoD Protein; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Transgenes; Tumor Cells, Cultured

2001
A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.
    Cancer research, 2001, Jul-01, Volume: 61, Issue:13

    Topics: Adenoviridae; Antigens, CD34; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Biotransformation; Bone Marrow Purging; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; DNA, Complementary; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cells; Humans; Irinotecan; Leukocytes, Mononuclear; Neuroblastoma; Prodrugs; Reverse Transcriptase Polymerase Chain Reaction; Transduction, Genetic; Tumor Cells, Cultured

2001
Clinical trials using irinotecan.
    Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Chromosome Breakage; Clinical Trials as Topic; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neuroblastoma; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays

2002